中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.04 seconds)

    HUMAN ANTIBODIES TO PD-1
    8.
    发明申请
    HUMAN ANTIBODIES TO PD-1 审中-公开

    公开(公告)号：US20200330794A1

    公开(公告)日：2020-10-22

    申请号：US16919296

    申请日：2020-07-02

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. Papadopoulos ,  Andrew J. Murphy ,  Gavin Thurston ,  Ella Ioffe ,  Elena Burova

    IPC: A61N5/10 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.

    Human Antibodies to PD-L1
    10.
    发明申请
    Human Antibodies to PD-L1 有权
    PD-L1的人抗体

    公开(公告)号：US20150203580A1

    公开(公告)日：2015-07-23

    申请号：US14603808

    申请日：2015-01-23

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. Papadopoulos ,  Andrew J. Murphy ,  Gavin Thurston ,  Ella Ioffe ,  Elena Burova

    IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

    CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

    Abstract translation: 本发明提供结合T细胞共抑制剂配体编程的死亡配体1（PD-L1）蛋白的抗体及其使用方法。 在本发明的各种实施方案中，抗体是与PD-L1结合的完全人抗体。 在某些实施方案中，本发明提供包含结合PD-L1的第一结合特异性和结合肿瘤细胞抗原的第二结合特异性，感染的细胞特异性抗原或T细胞特异性抗原的多特异性抗原结合分子， 细胞共抑制剂。 在一些实施方案中，本发明的抗体可用于抑制或中和PD-L1活性，从而提供治疗疾病或病症如癌症或病毒感染的方法。

Patent Agency Ranking